PHOFAY ACNE SPOTTREATMENT Cream
- Manufacturer
- Hangzhou Jingshen Trading Co., Ltd.
- Effective date
- 2025-08-26
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 01:12:42
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
SALICYLIC ACID1.08%
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
lf Swallowed, Get Medica Help or Contact a Poison Control Center right away
WARNINGS SECTION
For external use only
When using this product
skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time. lf irritation occurs, only use one topical acne medication at a time.
DOSAGE & ADMINISTRATION SECTION
Directions
clean the skin thoroughly before applying this product
cover the entire affected area with a thin layer one to three times daily
because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor
if bothersome dryness or peeling occurs, reduce application to once a day or every other day.
INACTIVE INGREDIENT SECTION
Water, Butylene Glycol, Caprylic/Capric Triglyceride,Cetyl Ethylhexanoate, Propylene Glycol, Dimethicone Cetearyl Alcohol, C14-22 Alcohols, Glyceryl Stearate,Niacinamide, Betaine,PEG-100 Stearate, 1,2-Hexanediol,Hydroxyacetophenone, Sodium Hydroxide, PEG-40 Hydrogenated Castor Oil, C12-20 Alkyl Glucoside,Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Xanthan Gum,Centella Asiatica Root Extract, Menthol, Dipotassium Glycyrrhizate, Citric Acid, lron Oxides (Cl 77492)
OTHER SAFETY INFORMATION
protect the product in this container from excessive
heat and direct sun
OTC - PURPOSE SECTION
Acne treatment
INDICATIONS & USAGE SECTION
For the treatment of acne
Reduces the number of acne blemishes
Helps prevent the development of new acne pimples
OTC - QUESTIONS SECTION
Call 1-818-579-7288 or 1-818-688-3208
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed RxNorm Mappings#
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| d1c9d1af-bddd-448d-86f7-69052b7d5b47 | Product name | 1 | 20220627 |
| dea2eded-d1e7-46bb-9a3d-f8dc20de6277 | Product name | 1 | 20190408 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 87080-101-01 | PHOFAY ACNE SPOTTREATMENT Cream | 1 g in 1 BOTTLE | CREAM | 1 | 1 | |
| 87080-101-01 | PHOFAY ACNE SPOTTREATMENT Cream | 1 in 1 BOX | CREAM | 1 | 1 |
Products#
Every source-derived product name is available through these pages.
- PHOFAY ACNE SPOTTREATMENT Cream
- Salicylic Acid
- HYDROXYACETOPHENONE
- DIPOTASSIUM GLYCYRRHIZATE
- DIPROPYLENE GLYCOL
- CETEARYL ALCOHOL
- C14-22 ALCOHOLS
- PEG-40 HYDROGENATED CASTOR OIL
- DIMETHICONE
- CENTELLA ASIATICA ROOT
- SODIUM HYDROXIDE
- NIACINAMIDE
- C12-20 ALKYL GLUCOSIDE
- MENTHOL
- CETYL ETHYLHEXANOATE
- WATER
- BUTYLENE GLYCOL
- PEG-100 STEARATE
- 1,2-HEXANEDIOL
- ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER (60000 MPA.S)
- XANTHAN GUM
- CAPRYLIC/CAPRIC TRIGLYCERIDE
- BETAINE
- CITRIC ACID
- CI 77492
- GLYCERYL STEARATE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 87080-101 | 87080-101-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| PHOFAY ACNE SPOTTREATMENT Cream | SALICYLIC ACID | Hangzhou Jingshen Trading Co., Ltd. | 3d40c687-7110-46b1-e063-6394a90a8416 | 2025-08-26 | Warnings | 87080-101-01 87080-101 87080010101 3d40c687-7111-46b1-e063-6394a90a8416 3d40c687-7110-46b1-e063-6394a90a8416 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
